Lung Cancer | Specialty

Dr. Fidler on Novel Chemotherapy Strategies in Nonsquamous NSCLC

June 18th 2019

Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.

Dr. Ou on the FDA Approval of Pembrolizumab in SCLC

June 18th 2019

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).

FDA Approves Pembrolizumab for Metastatic SCLC

June 18th 2019

The FDA has granted an accelerated approval to single-agent pembrolizumab for the treatment of patients with metastatic small cell lung cancer who have disease progression on or after platinum-based chemotherapy and ≥1 other prior line of therapy.

Immunotherapy Revolutionizes Squamous NSCLC, But Biomarker Enhancement Needed

June 17th 2019

Chad Pecot, MD, discusses practice-changing immunotherapy research that has read out in squamous non–small cell lung cancer, emerging biomarkers under investigation, and logical combinations that beg for further exploration.

Novel Approaches Seek to Enhance Efficacy of Osimertinib in EGFR+ NSCLC

June 14th 2019

Jeffrey M. Clarke, MD, discusses the optimal targeted therapies for the frontline treatment of patients with EGFR-positive NSCLC and sequencing beyond progression.

Dr. Kris on Predicting Benefit With Osimertinib in EGFR+ NSCLC

June 13th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses methods for predicting benefit with osimertinib (Tagrisso) in patients with EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Garassino on Erlotinib/Ramucirumab Versus Osimertinib in EGFR+ NSCLC

June 13th 2019

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the combination of erlotinib (Tarceva) and ramucirumab (Cyramza) versus osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Clarke on Combination Approaches Beyond Progression on Osimertinib in Lung Cancer

June 12th 2019

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses combination approaches beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Bazhenova on Sequential Use of Immunotherapy and EGFR TKIs in Lung Cancer

June 11th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses research that has looked at the use of EGFR TKIs after immunotherapy in patients with EGFR-mutant non–small cell lung cancer.

Dr. Zhu on TMB in Lung Cancer

June 8th 2019

Viola W. Zhu, MD, PhD, medical oncologist/hematologist, University of California, Irvine, discusses tumor mutational burden (TMB) in lung cancer.

Brigatinib Elicits Responses in ALK+ NSCLC Following Next-Generation TKIs

June 7th 2019

Brigatinib demonstrated promising response rates in patients with ALK-positive non–small cell lung cancer who have progressed on treatment with another next-generation ALK TKI, according to preliminary phase II results presented at the 2019 ASCO Annual Meeting.

Dr. Ou on Investigational KRAS Inhibitors in Lung Cancer

June 7th 2019

Sai-Hong I. Ou, MD, PhD, professor, Division of Hematology/Oncology, Department of Medicine, University of California Irvine School of Medicine, discusses investigational KRAS inhibitors in lung cancer.

Dr. Bauml on the Use of Immunotherapy in Oligometastatic NSCLC

June 6th 2019

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of immunotherapy in oligometastatic non–small cell lung cancer.

Dr. Ready on the Benefit of PD-L1 Inhibition in SCLC

June 5th 2019

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses the benefit of PD-L1 inhibition in small cell lung cancer.

Evolutions in the Treatment of EGFR-Mutated NSCLC

June 4th 2019

Sequencing With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Second- and Third-Generation TKIs in EGFR-Mutated NSCLC

June 4th 2019

Treating With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Resistance to Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

June 4th 2019